NIH R01 · 2024
Targeting PEN-GPR83 as a as a strategy to reduce opioid abuse liability
Project Summary/Abstract: Targeting PEN-GPR83 as a strategy to reduce opioid abuse liability. Opioid medications, such as morphine and oxycodone, are mainline treatments for pain, however, their use is limited by side effects such as tolerance, dependence, and addiction. Our data demonstrate that GPR83 antagonist Cpd 25, blocks morphine reward while enhancing morphine antinociception suggesting that GRP83-based targeting could be used to reduce the abuse liability of opioids while enhancing their analgesic effects. The first step in validating the potential of GPR83 as a target to reduce abuse liability is to unravel the neurobiological mechanisms by which GPR83 interacts with the…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.